Objective: The use of second-generation antipsychotics (SGAs) in youth has increased considerably. Increases are mainly attributable to treatment of disruptive behaviour disorders (DBDs). Our objective was to review the evidence regarding the efficacy of SGAs for DBDs in youth.
Clinical Implications
• There is good evidence to support the short-term efficacy of risperidone for the treatment of DBDs in children with subaverage IQs.
• Evidence is weak for the use of SGAs in the treatment of DBDs in children with average IQs.
Limitations
• All published RCTs have been funded by pharmaceutical companies.
• The number of published studies and the number of participants in these studies is modest.
D uring the past decade, the use of SGAs in children and adolescents has increased considerably in Canada 1 and other developed countries. 2 Increases in medication use have been mainly attributable to the prescription of SGAs for a wide variety of nonpsychotic disorders, with the greatest increase for the treatment of the DBDs. The increased use of SGAs in Canadian youth is concerning, particularly because the only pediatric approval of an SGA by Health Canada is for aripiprazole in adolescents (aged 16 years and older) with schizophrenia. Further, SGAs are associated with metabolic and neurological side effects that require monitoring and vigilance on the part of both the practitioner and the parent. 3 Our objective was to review the evidence for the efficacy of SGAs in children with DBDs in an effort to clarify how strongly the literature supports their increased use for this indication in clinical practice.
Methods
We searched for all RCTs of SGAs, compared with placebo, for the treatment of DBDs (such as ADHD, ODD, and CD, as well as aggressive behaviour in children with these disorders). Both the MEDLINE and Embase databases were searched, from 1996 to September of 2011, for relevant articles (see MEDLINE search strategy in online eAppendix 1). Studies comparing SGAs to an active comparator were excluded, as were open-label studies. There were no restrictions about language of publication or size of study. All abstracts retrieved from the searches were examined by 2 reviewers, independently, for potential inclusion. Full text articles of relevant abstracts were retrieved and read in detail by each reviewer, independently. Data were abstracted in duplicate onto predesigned summary forms and confirmed for accuracy. The methodological quality of studies was evaluated using quality criteria proposed by the US Preventive Services Task Force. 4 Based on fulfillment of quality criteria, studies were rated as good, fair, or poor (see list of quality criteria in online eAppendix 2).
For the purposes of this review, we focused on drug efficacy data. For information on adverse events, the reader is referred to a published systematic review of adverse effects related to SGA use in children. 5
Results
A total of 8 RCTs of SGAs, compared with placebo, in youth with DBDs were included in this systematic review (online eTable 1). Methodological quality of included studies was good or fair for all included trials. All studies were sponsored by pharmaceutical companies. We found 2 additional RCT protocols registered on the clinical trials.gov website, for which no results were available through the website or in the published literature. This included 1 RCT of aripiprazole for ADHD with partial or no response to stimulants, and 1 RCT of ziprasidone for CD or other DBDs.
Five RCTs have evaluated the use of risperidone in youth with the combination of subaverage-borderline IQ and disruptive behaviour-aggression. [6] [7] [8] [9] Single RCTs have evaluated the use of risperidone for treatment-resistant aggression in ADHD 10 and for the treatment of CD, 11 and a single RCT has evaluated the use of quetiapine for adolescent CD. 12 Snyder et al 13 performed a 6-week double-blind study of 110 children, aged 5 to 12 years, with an IQ between 36 and 84, a DBD (DSM-IV diagnosis of CD, ODD, or DBD-NOS), and a score of at least 24 on the Conduct Problem subscale normale à des adolescents au développement normal; la facilité de titration des ADG et la perception erronée que très peu de surveillance suffit; la non-disponibilité de traitements psychosociaux; la familiarité limitée avec d'autres options pharmacologiques; les normes cliniques et culturelles; et l'influence de l'industrie pharmaceutique.
of the NCBRF, parent version. Eighty per cent of subjects had comorbid ADHD. The mean dosage of risperidone was 0.98 mg daily, given once in the morning. Subjects taking previously prescribed stable dosages of psychostimulants for 30 days prior to trial entry were included. The primary outcome variable for the study was the Conduct Problem subscale of the NCBRF at week 6 of the double-blind treatment phase. Children completed a 1-week, single-blind placebo, run-in period to exclude placebo responders.
One hundred and thirty-three children were admitted to the study: 23 were placebo responders, leaving 110 children who were randomized to treatment with risperidone or placebo. The placebo and risperidone groups did not differ in any baseline demographic features. Twenty-five children discontinued before completion of the trial: 19 from the placebo group and 6 from the risperidone group. All 19 children in the placebo group discontinued because of insufficient response, compared with 2 children in the risperidone group (P < 0.001). Changes from baseline to end point on the Conduct Problem subscale of the NCBRF were significantly greater in the risperidone group, compared with the placebo group, with a decline in symptom ratings of 6.8 points with placebo and 15.8 points with risperidone (P < 0.001). A significant effect was demonstrated from the first week of treatment onward. In addition to the primary end point, numerous secondary efficacy variables showed significant improvement, including all 5 subscales of the ABC.
Aman et al 7 performed an identical study to Snyder et al 13 in 118 children, using the same study design, inclusion criteria, and outcome measures. Demographic characteristics of the risperidone and placebo groups differed regarding IQ, with a mean IQ of 66 in the placebo group and 70 in the risperidone group (P < 0.04). Because of this difference, IQ was controlled for statistically. Twelve risperidone subjects and 19 placebo subjects withdrew prematurely. Discontinuation owing to insufficient response occurred in 15 placebo subjects, compared with 4 risperidone subjects.
The mean dosage of risperidone at end point was 1.16 mg daily. The risperidone group had a significantly greater decrease in the Conduct Problem subscale of the NCBRF, compared with the placebo group, at end point, with a decrease in score of 15.2 points, compared with 6.2 points with placebo (P < 0.001). A significant difference in mean change scores between groups occurred at week 1 of the trial and was maintained throughout the 6-week study. Compared with placebo, risperidone-treated children had significantly greater improvement on numerous secondary efficacy variables, including all other subscales of the NCBRF and 3 of 5 subscales of the ABC.
Van Bellinghen and De Troch 6 performed a 4-week RCT in 13 children and adolescents in residential care with subaverage-borderline IQ and disruptive behaviouraggression. Patients aged 6 to 18 years who had IQs between 45 and 85 and demonstrated persistent behavioural disturbances (hostility, aggressiveness, irritability, agitation, or hyperactivity) were eligible for inclusion. Antiepileptic medications were allowed during the trial, but other psychotropics were not permitted. Subjects received a mean dosage of 1.2 mg daily, given in the evening. A primary outcome measure was not specified, but subjects were assessed at baseline and end point using the ABC, CGI scale, and various other scales.
There were no significant differences between treatment groups at baseline, and all patients completed the study. Significant differences between risperidone and placebo at end point were noted in 3 of the ABC subscales and the CGI mean scores. The ABC total score decreased by 30.3 points with risperidone, compared with 3.3 points with placebo (P < 0.01). Mean score on the CGI decreased by 2.2 points in the risperidone group, compared with 0.2 points in the placebo group (P < 0.05). Five of 6 subjects randomized to risperidone were rated as much or very much improved, compared with none of the 7 subjects randomized to placebo.
Buitelaar et al 8 compared risperidone to placebo for aggression in a 10-week trial of 38 hospitalized adolescents with subaverage IQ. Study subjects were institutionalized for a chronic pattern of repetitive aggressive behaviour that was refractory to outpatient treatment approaches, although not all patients had received prior drug therapy. Subjects were included in the study if they were aged between 12 and 18 years with a principal diagnosis of CD, ODD, or ADHD and a full-scale IQ between 60 and 90. Subjects had to have overt aggressive behaviour that persisted during hospitalization and failed to respond to behavioural treatment approaches. The use of concomitant psychotropics was not permitted during the double-blind treatment phase of the study. The mean dosage of risperidone in the trial was 2.9 mg daily (total; administered twice daily). The primary efficacy measure was the overall severity of the subject's condition, as assessed by a psychiatrist on the CGI-S scale. The trial design included a 2-week baseline period, a 6-week double-blind treatment period, and a 2-week washout period. Patients were permitted to take psychotropics during the 2-week baseline period, but it was discontinued at the beginning of the 6-week double-blind treatment phase.
Two subjects in the placebo group stopped treatment during the double-blind period because of lack of improvement and uncontrollable aggressive behaviour. One subject in the risperidone group terminated the study following 1 week in the washout period because of unmanageable aggression. On the primary outcome measure, risperidone was superior to placebo after 2 weeks of treatment and throughout the remainder of the treatment period. Mean CGI-S scores were 4.3 (SD 1.4) at baseline and 2.7 (SD 1.2) at end point in the risperidone group, in contrast to 4.2 (SD 0.9) at baseline and 4.4 (SD 1.0) at end point in the placebo group (P < 0.001). During the washout period, subjects treated with risperidone showed a significantly greater deterioration than placebotreated subjects. The OAS and ABC were used as secondary measures and were completed separately by ward staff and teachers. Subjects in the risperidone group showed significant improvement in scores at end point, compared with baseline, while the placebo group did not. However, differences in change scores between groups were not significant, with the exception of the change in overall ABC score as rated by teachers.
Reyes et al 9 performed an RCT of risperidone maintenance treatment in children and adolescents meeting DSM-IV criteria for CD, ODD, or DBD-NOS. This study had 335 subjects with normal or subaverage IQ (that is, an IQ of 56 or more). Inclusion required that the conduct problem be serious enough to warrant treatment with risperidone, as well as a score of 25 or more on the Conduct Problem subscale of the NCBRF, parent version. Concomitant therapy with a stable dose of psychostimulant was permitted. Subjects who had previously responded to risperidone treatment during 12 weeks were randomly assigned to 6 months of double-blind risperidone or placebo. The primary outcome was the time to symptom recurrence, which was defined as sustained deterioration on either the CGI-S rating (of 2 or more points) or the Conduct Problem subscale of the NCBRF (of 7 or more points). Risperidone dosage was based on weight, with patients less than 50 kg receiving 0.25 to 0.75 mg daily, and patients more than 50 kg receiving 0.5 to 1.5 mg daily (given once daily or twice in divided doses).
Five hundred and twenty-seven subjects entered the initial open-label, 6-week risperidone acute treatment phase. Among these, 436 subjects continued 6 weeks of singleblind risperidone therapy (the single-blind phase was employed to ensure that the patient and the caregiver were unaware of the exact timing of the randomization to risperidone or to placebo). Among the 91 subjects who did not continue, 52 stopped because of nonresponse. Three hundred and thirty-five subjects then entered the 6-month, double-blind maintenance treatment; of the 101 children who did not continue, 61 stopped because of nonsustained response. In the maintenance phase, 172 subjects were randomized to risperidone and 163 to placebo. At the end of this period, a significant difference was found in the rates of symptom recurrence, with 27.3% of subjects assigned to risperidone meeting criteria for recurrence, compared with 42.3% assigned to placebo (P = 0.002). Further, symptom recurrence occurred in 25% of subjects after 119 days with risperidone, compared with 37 days with placebo (P < 0.001).
Armenteros et al 10 evaluated the efficacy of risperidone augmentation for treatment-resistant aggression in an RCT involving 25 children (aged 7 to 12 years) with ADHD on a constant dose of a psychostimulant. Subjects had aggressive behaviours that failed to respond to psychostimulant therapy as documented by 3 acts of aggression in the past week, 2 of which had to be acts of physical aggression against other people, objects, or self. Full-scale IQ had to be 76 or more. Children were randomized to risperidone (mean dosage 1.08 mg daily [at bedtime]) or placebo for 4 weeks, and the primary outcome measures were total score changes from baseline on the CAS-P and the CAS-T.
Among the 25 children included in the study, 13 had comorbid ODD and 6 had comorbid CD. On both the CAS-P and the CAS-T, no significant difference was found between risperidone and placebo in the change in total score, with the 2 groups improving by a similar magnitude during 4 weeks of treatment. Nonetheless, the authors highlighted a significant difference in the proportion of children improving by 30% or more on the CAS-P, with 12 of 12 risperidone-treated subjects achieving this level of improvement, compared with 10 of 13 placebo-treated subjects (P < 0.05).
Findling et al 11 evaluated the use of risperidone in the treatment of children and adolescents with a primary diagnosis of CD with prominent aggressive behaviour. This was a 10-week RCT in 20 youth (aged 5 to 15 years), and the primary outcome measure was the RAAPP, a cliniciancompleted global rating scale of aggression (scored 1 to 5). Subjects were excluded if they had moderate-to-severe ADHD or other significant psychiatric comorbidity, or if they were being treated with psychotropics. The dosage of risperidone ranged from 0.75 to 1.5 mg daily, administered in the morning.
While the difference between groups in RAAPP scores at week 10 was not significant, the mean change in RAAPP score from baseline to week 10 was significantly greater in subjects treated with risperidone (-1.65), compared with placebo (-0.16) (P = 0.03). Significant differences between the risperidone and placebo groups were also seen for secondary outcome measures, including the CGI-S and CGI-I scales, the Conduct Problem subscale of the CPRS, and the Delinquent Behaviour subscale of the CBCL; however, the difference in the Aggressive Behaviour subscale of the CBCL was nonsignificant.
Connor et al 12 evaluated the use of quetiapine for the treatment of CD in a 7-week RCT in 19 adolescents. Eligible subjects were aged 12 to 17 years and had a primary psychiatric diagnosis of CD, with moderate-tosevere aggressive behaviour based on an OAS score of 26 or more and a CGI-S score of 4 or more. Subjects with significantly subaverage IQ and concurrent administration of any psychoactive medication were excluded. Participants were given a single-blind placebo for 1 week, and those no longer meeting entrance criteria at week 2 (randomization) were excluded from further participation. Quetiapine and placebo were administered twice daily, with gradual titration to a minimal dosage of 200 mg daily and up to 800 mg daily based on clinician-assessed benefits and patient tolerability. The clinician-rated CGI-S and CGI-I scales were the primary outcome measures.
Significant differences at baseline between groups included the age of subjects, which was significantly lower in the quetiapine group, compared with the placebo group (13.1 and 15.0 years, respectively), and a history of legal involvement, which was present in 33% of the quetiapine group and 100% of the placebo group, respectively. Rates of comorbidity were high in both groups; 95% had ODD and 79% had ADHD. The mean dosage of quetiapine, administered twice daily, at study end point was 294 mg daily (SD 78). CGI-S scores decreased from 5.9 at randomization to 3.4 at end point in the quetiapine group, compared with a decrease from 5.5 to 5.0 with placebo (P = 0.007). Further, at study end point, 8 of 9 subjects randomized to quetiapine were judged improved (a CGI-I score of 2 or less), compared with only 1 of 10 subjects randomized to placebo (P < 0.001). Changes in secondary outcomes, including the OAS and the CPRS, were not significantly different between groups, though the study was not adequately powered for these analyses.
Discussion
An important finding of our review of SGAs for disruptive behaviour is that 4 placebo-controlled studies support the short-term (that is, 10 weeks or less) efficacy of low-dosage risperidone (about 1 mg daily in 3 of the 4 studies) in youth with subaverage IQs. However, placebocontrolled evidence is limited for adolescents as only 2 of the 4 studies included youth aged 13 years and older, and both of these were small. 6, 8 One maintenance study of lowdosage risperidone in youth aged 5 to 17 years supported its efficacy during a 6-month period, but even so, close to 60% of subjects randomized to placebo did not experience recurrence of symptoms. 9 The latter result suggests that even when patients do well with risperidone, tapering the medication is reasonable after several months of stability, especially if adverse effects become problematic.
Our review also found that placebo-controlled evidence is weak or nonexistent for SGAs, other than risperidone, and it is weak in youth with average IQs. In fact, only 3 small studies in youth with average IQs and disruptive behaviour have been published, totalling 64 subjects. The study by Armenteros et al 10 with risperidone was negative on both primary outcome measures, the one by Findling et al 11 with risperidone was positive on most but not all primary and secondary outcome measures, and the one by Connor et al 12 with quetiapine was positive on both primary outcome measures but only 1 of 3 secondary measures. Note, in the Armenteros et al study 10 all subjects had ADHD and were on a constant dose of a psychostimulant, whereas the Findling et al study 11 excluded subjects who had moderateto-severe ADHD or were taking another psychotropic, and the Connor et al study 12 also excluded subjects taking another psychotropic, even though 79% of included subjects had ADHD. Thus, regarding the common practice of augmenting a psychostimulant with an SGA to target aggression associated with ADHD, placebo-controlled evidence is extremely limited and the evidence that exists is essentially negative. In contrast, multiple placebocontrolled and other rigorously designed studies support the use of psychostimulants alone to treat aggression associated with ADHD, particularly when psychostimulant treatment is carefully monitored and adjusted (for example, different dosages and formulations are tried) and is combined with behavioural therapy. [14] [15] [16] The evidence regarding the efficacy of SGAs for disruptive behaviour in youth, especially in those with average IQs, is highly incongruous with pediatric prescribing patterns for these agents in North America during the past 2 decades. Between 1995 Between -1996 Between and 2001 Between -2002 , the frequency of antipsychotic prescribing for American youth was found to increase from 8.6 to 39.4 per 1000. 17 In almost 30% of youth, the diagnosis was ADHD or CD, whereas less than 8% had a pervasive developmental disorder or an intellectual disability. Similar results were found in another American study 2 during roughly the same time period, and in this report, 90% or more of antipsychotic prescriptions were for an SGA. More recent data reveal that American prescription rates of SGAs continued to increase in youth through 2006, 18 and doubled in preschoolers (aged 2 to 5 years) from 1999 to 2007. 19 While pediatric prescriptions of antipsychotics are still less frequent in Canada, compared with the United States, the pattern of increasing use is similar. Between 1999 and 2008, the rate of antipsychotic use in Manitoba youth increased from 1.9 to 7.4 per 1000, despite a sharp decline in prescriptions for firstgeneration antipsychotics. 20 In addition, antipsychotic recommendations for youth across Canada were found to increase by 114% from 2005 to 2009, by which point 95% of the recommendations were for an SGA. 1 In both Canadian studies, the most common indication for the antipsychotic was ADHD, with CD ranking second or third.
Given the growing evidence regarding weight gain, metabolic abnormalities, and other adverse effects associated with SGAs, considerable concern has been raised about the increasing use of these agents in children and adolescents. 5, 21, 22 However, what appears to be underappreciated is the paucity of data supporting the efficacy of SGAs for disruptive behaviour in youth with average IQs, even though this is the most common clinical situation in which SGAs are prescribed. Multiple factors likely account for the disconnect between the evidence and clinical practice, including extrapolation from studies in youth with autism or subaverage IQs 7,13,23 ; ease of SGA titration and the mistaken perception that little monitoring is required 24, 25 ; unavailability of psychosocial treatment alternatives 26 ; limited familiarity or comfort with other pharmacological options (for example, psychostimulants, antidepressants, alpha-agonists, lithium, and anticonvulsants); clinical and cultural norms; and the influence of the pharmaceutical industry. 27, 28 Limitations of our review relate mainly to the nature of the available literature: the number of published studies is modest; sample sizes are generally small (particularly for youth with average IQs and for adolescents); the quality of most studies is only fair (online eAppendix 2); unpublished data are not readily available, and therefore could not be reviewed; and all published studies were funded by drug companies. These limitations along with our findings highlight the need for further research that is nonindustryfunded and includes the kinds of patients that are most frequently treated with SGAs. An urgent need also exists for increased medical education and community resources that promote evidence-based treatment for disruptive and aggressive youth, especially the provision of appropriate psychosocial interventions. 29, 30 
